CN1947717B - 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 - Google Patents

选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 Download PDF

Info

Publication number
CN1947717B
CN1947717B CN200610019893XA CN200610019893A CN1947717B CN 1947717 B CN1947717 B CN 1947717B CN 200610019893X A CN200610019893X A CN 200610019893XA CN 200610019893 A CN200610019893 A CN 200610019893A CN 1947717 B CN1947717 B CN 1947717B
Authority
CN
China
Prior art keywords
pain
alkyl
alkoxy
neuronal
camp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN200610019893XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1947717A (zh
Inventor
卓敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yongzhan Holdings Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN1947717A publication Critical patent/CN1947717A/zh
Application granted granted Critical
Publication of CN1947717B publication Critical patent/CN1947717B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200610019893XA 2005-10-14 2006-03-01 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用 Expired - Lifetime CN1947717B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72671805P 2005-10-14 2005-10-14
US60/726,718 2005-10-14

Publications (2)

Publication Number Publication Date
CN1947717A CN1947717A (zh) 2007-04-18
CN1947717B true CN1947717B (zh) 2012-09-26

Family

ID=37942274

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200610019893XA Expired - Lifetime CN1947717B (zh) 2005-10-14 2006-03-01 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用

Country Status (6)

Country Link
US (1) US8124599B2 (https=)
EP (1) EP1948182B1 (https=)
JP (1) JP5404045B2 (https=)
CN (1) CN1947717B (https=)
CA (1) CA2625553C (https=)
WO (1) WO2007041863A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
LT1976828T (lt) 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
AR065372A1 (es) 2007-02-19 2009-06-03 Smithkline Beecham Corp Derivados de purina
UA103195C2 (uk) 2008-08-11 2013-09-25 Глаксосмитклайн Ллк Похідні пурину для застосування у лікуванні алергій, запальних та інфекційних захворювань
EP2326646B1 (en) 2008-08-11 2013-07-31 GlaxoSmithKline LLC Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BRPI0917013A2 (pt) 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
WO2011098451A1 (en) 2010-02-10 2011-08-18 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
US9050319B2 (en) 2010-04-30 2015-06-09 Telormedix, Sa Phospholipid drug analogs
AU2011247358B2 (en) 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
HRP20181667T1 (hr) 2011-07-22 2018-12-14 Glaxosmithkline Llc Pripravak
EA026354B1 (ru) 2012-08-24 2017-03-31 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Пиразолопиримидиновые соединения
AU2013348217B2 (en) 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
AU2014249168B2 (en) 2013-03-12 2018-07-12 Celltaxis, Llc Methods of inhibiting leukotriene A4 hydrolase
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
CA2906035A1 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
WO2014152536A2 (en) 2013-03-14 2014-09-25 Celtaxsys, Inc. Inhibitors of leukotriene a4 hydrolase
TWI731317B (zh) 2013-12-10 2021-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EA201791336A1 (ru) 2014-12-18 2017-10-31 Джензим Корпорейшн Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)
JP6902336B2 (ja) * 2016-08-01 2021-07-14 永展国際有限公司Ｆｏｒｅｖｅｒ Ｃｈｅｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｌｉｍｉｔｅｄ ５−［２−［（６−アミノ）−９ｈ−プリン−９−イル］エチルアミノ］−１−ペンタノール多結晶体
JP7332841B2 (ja) * 2017-05-20 2023-08-24 永展控股有限公司 疼痛を治療するための薬用組成物
ES3014615T3 (en) 2018-05-31 2025-04-23 Celltaxis Llc Method of reducing pulmonary exacerbations in respiratory disease patients
CN108853110B (zh) * 2018-08-24 2020-07-28 江苏理工学院 一种化合物a8作为组蛋白甲基转移酶nsd3活性抑制剂及其应用
CN114931561B (zh) * 2022-05-25 2024-02-02 青岛永展医药科技有限公司 一种治疗慢性痛的胶囊组合物及其制备方法
CN118526502A (zh) * 2024-07-24 2024-08-23 浙江永展医药科技有限公司 腺苷酸环化酶抑制剂用于制备治疗围手术期疼痛药物的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2844577A (en) * 1958-07-22 Certificate of correction
US2691654A (en) 1952-06-11 1954-10-12 Buroughs Wellcome & Co U S A I Amino heterocycles and method of making
US3691654A (en) * 1969-05-29 1972-09-19 Gen Electric Metal foil lead manufacture
US4189485A (en) * 1977-08-23 1980-02-19 Takeda Chemical Industries, Ltd. Purine derivatives
JPS6058726B2 (ja) * 1977-10-05 1985-12-21 日本臓器製薬株式会社 プリン誘導体を有効成分として含有する抗アレルギ−，鎮痛，鎮静剤
JPS61171423A (ja) 1985-01-24 1986-08-02 Advance Res & Dev Co Ltd 抗う蝕乃至抗歯周症剤
GB0100623D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds IV
AU2002303023A1 (en) 2002-06-05 2003-12-22 Metabolic Engineering Laboratories Co., Ltd. Signals and molecular species involved in senescence
US20040013669A1 (en) 2002-06-12 2004-01-22 Feng Wei Method for treating persistent pain and identifying compounds to treat persistent pain
RU2233842C1 (ru) * 2003-01-13 2004-08-10 Петров Владимир Иванович Производные пурина, обладающие противовирусной активностью
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
US20080221060A1 (en) 2004-03-05 2008-09-11 Martyn Pritchard Therapeutic Compounds
WO2005092306A1 (en) 2004-03-11 2005-10-06 The General Hospital Corporation Methods and compositions for modulating opioid tolerance and chronic pain
WO2006002422A2 (en) * 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037159A2 (en) * 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KHASAR S. G. et al.Epinephrine Produces a β-Adrenergic Receptor-Mediated Mechanical Hyperalgesia and In Vitro Sensitization of Rat Nociceptors.Journal of Neurophysiology.1999,81(3),p.1107右栏第2-4行. *

Also Published As

Publication number Publication date
JP5404045B2 (ja) 2014-01-29
CA2625553A1 (en) 2007-04-19
CN1947717A (zh) 2007-04-18
US20090233922A1 (en) 2009-09-17
US8124599B2 (en) 2012-02-28
CA2625553C (en) 2014-03-11
EP1948182A4 (en) 2009-08-19
EP1948182A1 (en) 2008-07-30
WO2007041863A1 (en) 2007-04-19
EP1948182B1 (en) 2012-12-12
JP2009511508A (ja) 2009-03-19

Similar Documents

Publication Publication Date Title
CN1947717B (zh) 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
JP6991993B2 (ja) 痛覚過敏を治療する方法
JP6509386B2 (ja) ｍＴＯＲ経路関連疾患を治療するための化合物
WO2017143014A1 (en) Jak inhibitors and uses thereof
US10689324B2 (en) Metabolism resistant fenfluramine analogs and methods of using the same
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
US20200016233A1 (en) Molecular Composition for Enhancing and Rejuvenating Maintenance and Repair of Mammalian Tissues
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
KR20170092543A (ko) 슈퍼-인핸서 부위에서 전사 조절을 표적화하는 방법
Guagnini et al. Erectile properties of the Rho-kinase inhibitor SAR407899 in diabetic animals and human isolated corpora cavernosa
KR20180124976A (ko) 신경교종을 포함하는 암을 치료하기 위해 에플로르니틴 및 이의 유도체 및 동족체를 사용하기 위한 조성물 및 방법
US20180318298A1 (en) Method of Treating Obesity
US20190365671A1 (en) Compounds, compositions and methods for treating oxidative dna damage disorders
US20190046530A1 (en) Phase 2 inducers and related signaling pathways protect cartilage against inflammation, apoptosis and stress
Zhao et al. (6aR)-11-amino-N-propyl-noraporphine, a new dopamine D2 and serotonin 5-HT1A dual agonist, elicits potent antiparkinsonian action and attenuates levodopa-induced dyskinesia in a 6-OHDA-lesioned rat model of Parkinson's disease
KR20230074533A (ko) Csf1r 키나아제 억제제 및 이의 용도
US6319944B1 (en) Aryl amidines, compositions containing such compounds and methods of use
Schutsky et al. Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled β2-adrenergic signaling
KR20230017357A (ko) 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물
Robotka et al. Systemically administered glucosamine-kynurenic acid, but not pure kynurenic acid, is effective in decreasing the evoked activity in area CA1 of the rat hippocampus
Lambert et al. Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate
WO2018237174A2 (en) CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS FOR THE TREATMENT OF DOMINANT AUTOMATIC RENAL POLYKYSTOSIS
JP2020500197A (ja) 骨格筋肥大誘発剤としてのｌｓｄ１阻害剤
BRPI0820652A2 (pt) mequitazina para tratar ou prevenir patologias envolvendo receptores h4 da histamina
US9017735B2 (en) Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160707

Address after: Hongkong, China

Patentee after: Forever Cheer International Ltd.

Address before: Ontario

Patentee before: Zhuo Min

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070418

Assignee: Shanghai forever Pharmaceutical Technology Co., Ltd.

Assignor: Forever Cheer International Ltd.

Contract record no.: 2017990000100

Denomination of invention: Method for treating neuronal and non-neuronal pain

Granted publication date: 20120926

License type: Common License

Record date: 20170324

EE01 Entry into force of recordation of patent licensing contract
EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20070418

Assignee: Zhejiang forever exhibition Medical Technology Co.,Ltd.

Assignor: Forever Cheer International Ltd.

Contract record no.: 2017990000436

Denomination of invention: Method for treating neuronal and non-neuronal pain

Granted publication date: 20120926

License type: Common License

Record date: 20171109

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20220823

Address after: 3/F, East China Commercial Building, 78 Bonham East Street, Sheung Wan, Hong Kong, China

Patentee after: Yongzhan Holdings Ltd.

Address before: Hong-Kong

Patentee before: Forever Cheer International Ltd.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20120926